Redoblado, Merlinda .
HRN: 19-71-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/09/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
11/09/2024
11/15/2024
IVT
2.25g
Q8
Chronic Otitis Media
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes